Search

Displaying results 1871 - 1880 of 4246 in total
  1. Drug

    Chlorprothixene

    go.drugbank.com/drugs/DB01239
    ApprovedInvestigationalWithdrawn

    Chlorprothixene is a typical antipsychotic drug of the thioxanthene (tricyclic) class. Chlorprothixene exerts strong blocking effects by blocking the 5-HT2 D1, D2, D3, histamine H1, muscarinic and alpha1 adrenergic receptors.

  2. Drug

    Ixekizumab

    go.drugbank.com/drugs/DB11569
    ApprovedInvestigational

    As IL-17A is a pro-inflammatory cytokine involved in inflammation and immune responses, blocking its effect is beneficial for use in inflammatory conditions.

  3. Drug

    Pralsetinib

    go.drugbank.com/drugs/DB15822
    ApprovedInvestigational

    Pralsetinib, similar to the previously approved selpercatinib, is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes. Enhanced RET (Rearranged during transfection) oncogene expres...

  4. Drug

    Patent Blue

    go.drugbank.com/drugs/DB13967
    ApprovedInvestigational

    Patent blue is aniline dye and it is one of the most common dyes used. It is a sodium or calcium salt of diethylammonium hydroxide inner salt. It has the chemical designation of (4-(alpha-(p-(diethylamino)phenyl)-2,4-disulfobenzylidene)-...

  5. Drug

    Digoxin Immune Fab (Ovine)

    go.drugbank.com/drugs/DB00076
    Approved

    It is used as an antidote for overdose of digoxin.

  6. Drug

    Antazoline

    go.drugbank.com/drugs/DB08799
    Approved

    It is also formulated as eye drops with naphazoline to relieve allergic conjunctivitis.

  7. Drug

    CHGN111

    go.drugbank.com/drugs/DB06376
    Experimental

    Numerous parameters of mitochondrial function are altered when the activity of CLK-1 is reduced, which results in a decrease of ROS at critical cellular sites, as well as in a decrease of systemic oxidative

  8. Drug

    Tiopronin

    go.drugbank.com/drugs/DB06823
    Approved

    As cystinuria is a relatively rare disease, tiopronin is classified as an orphan drug and is not patented in the United States. … Tiopronin is used as a second-line therapy to control the rate of cystine precipitation and excretion, and prevent kidney stone formation.

  9. Drug

    Icatibant

    go.drugbank.com/drugs/DB06196
    ApprovedInvestigational

    [A4017,A263041] It was investigated as a potential treatment of hereditary angioedema (HAE) as bradykinin was implicated in HAE swelling; specifically, mice lacking B<sub>2</sub> receptors showed reduced … [A4017,A263046] Icatibant was approved by the FDA on August 25, 2011, and by the EMA in 2008 as a treatment for hereditary angioedema.

  10. Drug

    Coagulation factor X human

    go.drugbank.com/drugs/DB13148
    ApprovedInvestigational

    Coagulation Factor X is a vitamin K-dependent, liver-produced serine protease that serves as the first enzyme in the coagulation cascade to form fibrin. … While Factor X normally circulates in the plasma as inactive molecules, the activation of Factor X is involved in both the intrinsic and extrinsic coagulation pathways.